News | May 13, 2023
Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
Pheezee is designed to assess musculoskeletal and neuromuscular health.
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Subscribe To Our Newsletter & Stay Updated
